To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with intermediate or high-risk myelodysplastic syndrome (MDS). Three of the total 11 MDS patients achieved complete remission (CR) and 6 achieved hematological improvement (HI), 1 stable disease (SD), and 1 progressive disease (PD). One patient was treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The median follow-up time was 413(90-1 275) d. Nine patients were still alive. Low dose subcutaneous decitabine combined with arsenic trioxide can be an alternative regimen for intermediate or high-risk MDS patients.
回顾性分析低剂量地西他滨皮下注射联合三氧化二砷诱导治疗11例中高危骨髓增生异常综合征（MDS）的安全性及疗效。所有患者均顺利完成治疗；11例MDS中，完全缓解3例，骨髓缓解伴血象不完全恢复（CRi）+血液学进步（HI）6例，疾病稳定1例，疾病进展1例。其中1例CRi+HI后行异基因造血干细胞移植。中位随访时间为413（90~1 275）d，9例存活至今。研究结果提示，对于中高危MDS，低剂量地西他滨皮下注射联合三氧化二砷治疗安全、有效。.
Keywords: Arsenic trioxide; Decitabine; Injections, subcutaneous; Low dose; Myelodysplastic syndromes.